|
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); DUBLIN - (Business Wire) Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "" report to their offering.Until a decade ago...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "" report to their offering.Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
DUBLINResearch and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "" report to their offering.Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but ...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners
Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the 'Colorectal Cancer Drug Pipeline Update 2010' report to their offering.Until a decade ago, 5FU/leucovorin formed the mainstay of...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
DUBLINResearch and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "" report to their offering.Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but ...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "Colorectal Cancer Drug Pipeline Update 2010" report to their offering.Until a decade ago, 5FU/leucovorin...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "Colorectal Cancer Drug Pipeline Update 2010" report to their offering.Until a decade ago, 5FU/leucovorin...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners
Research and Markets: - Find Competitors, Collaborations Partners & Candidates Etc DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the '' report to their...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Cand
Research and Markets: - Find Competitors, Collaborations Partners & Candidates Etc DUBLIN - (BUSINESS WIRE) - Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "" report to their...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates etc
Research and Markets (http://www.researchandmarkets.com/research/f23001/colorectal_cancer) has announced the addition of the "Colorectal Cancer Drug Pipeline Update 2010" report to their offering.Until a decade ago, 5FU/leucovorin formed the mainstay of...
|
|
|
Advisory Panel Rates Genomic Cancer Tests
Some genomic tests aimed at identifying patients most likely to respond to cancer drugs won a thumbs-up from a advisory panel, but others didn't make the grade.As part of a national coverage determination under way at the Centers for and Services, members of...
|
|
|
Colorectal Cancer Drug Pipeline Update 2010
Published Date: January 2010 Published By: Order Code: R474-371 Description Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard...
|
|
|
Idera Receives $4.3M with Merck KGaAs Initiation of a Phase II Head and Neck Cancer Trial
Cancer GEN News Highlights GEN News Highlights Idera Pharmaceuticalswill obtain 3.0 million (approximately $4.3 million) from Merck KGaA as a milestone fee under their worldwide licensing and collaboration agreement.The payment was triggered by Mercks...
|
|
|
Pfizer Strides Into Generics Pact
Pfizer, Inc.(PFE) Strides and its joint ventures with Aspen, Onco Laboratories Limited and Onco Therapies Limited, will supply the finished products to Pfizer. About 40 off-patent products, mostly oncology therapeutics, will be delivered by Strides under...
|
|
|
Enzon opens a Phase 2 study of PEG-SN38 for metastatic breast cancer
-- Enzon Pharmaceuticals, Inc.announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzons PEGylated form of SN38, the active metabolite of the cancer drug Camptosar...
|
|
|
Enzon Pharmaceuticals initiates treatment in Phase II breast canc...
Company: Enzon, Inc.(ENZN) Enzon Pharmaceuticals has reported that the first patient has been treated in the Phase II studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the...
|
|
|
Enzon Pharmaceuticals initiates treatment in Phase II breast cancer trial
Enzon Pharmaceuticals has reported that the first patient has been treated in the Phase II studies of PEG-SN38 for metastatic breast cancer.PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar.
|
|
|
Enzon begins phase-2 study of PEG-SN38 for metastatic breast cancer
Enzon Pharmaceuticals, Inc announced that the first patient has been treated in the phase-2 studies of PEG-SN38 for metastatic breast cancer.PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar ...
|
|
|
Enzon Opens A Phase 2 Study Of PEG-SN38 For Metastatic Breast Cancer
Enzon Pharmaceuticals, Inc.(Nasdaq: ENZN) today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer...
|
|
|
Medical News: Enzon Opens A Phase 2 Study Of PEG-SN38 For Metastatic Breast Cancer
Enzon Pharmaceuticals, Inc.(Nasdaq: ENZN) today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer...
|
|
|
Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer
Enzon Pharmaceuticals, Inc.announced that the first patient has been treated in the Phase 2 studies of PEGSN38 for metastatic breast cancer. PEGSN38 or EZN2208 is Enzons PEGylated form of SN38, the active metabolite of the cancer drug Camptosar.
|
|
|
Enzon Opens A Phase 2 Study Of PEG-SN38 For Metastatic Breast Cancer
Enzon Pharmaceuticals, Inc.recently announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug ...
|
|
|
Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer
BRIDGEWATER, N.J.(BUSINESS WIRE) Enzon Pharmaceuticals, Inc.(Nasdaq: ENZN) today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the...
|
|
|
Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38
Enzon Pharmaceuticals, Inc.(Nasdaq: ENZN) today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzons PEGylated form of SN38, the active metabolite of the cancer...
|
|
|
Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc.(Nasdaq: ENZN) today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon?s PEGylated form of SN38,...
|
